Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$38.6M Sell
698,666
-717,859
-51% -$38.9M 0.17% 89
2025
Q4
$69.5M Buy
1,416,525
+14,770
+1% +$689K 0.25% 67
2025
Q3
$60.5M Buy
1,401,755
+57,713
+4% +$2.25M 0.24% 75
2025
Q2
$51.6M Buy
1,344,042
+140,947
+12% +$5.39M 0.21% 86
2025
Q1
$46.6M Sell
1,203,095
-1,044,596
-46% -$38.2M 0.22% 96
2024
Q4
$76M Buy
2,247,691
+1,281,855
+133% +$46.1M 0.35% 54
2024
Q3
$39.5M Buy
965,836
+500,010
+107% +$20.5M 0.22% 83
2024
Q2
$17.9M Buy
465,826
+330,532
+244% +$13.9M 0.09% 165
2024
Q1
$5.8M Sell
135,294
-78,726
-37% -$3.25M 0.03% 357
2023
Q4
$7.93M Buy
214,020
+35,982
+20% +$1.29M 0.04% 289
2023
Q3
$6.45M Sell
178,038
-13,099
-7% -$465K 0.04% 311
2023
Q2
$6.81M Buy
191,137
+36,485
+24% +$1.31M 0.04% 252
2023
Q1
$5.5M Buy
154,652
+21,674
+16% +$758K 0.03% 292
2022
Q4
$4.67M Buy
132,978
+45,317
+52% +$1.51M 0.03% 373
2022
Q3
$2.58M Buy
87,661
+14,332
+20% +$543K 0.01% 508
2022
Q2
$3.99M Sell
73,329
-5,232
-7% -$289K 0.02% 547
2022
Q1
$4.28M Buy
78,561
+4,291
+6% +$233K 0.02% 507
2021
Q4
$4.09M Sell
74,270
-21,442
-22% -$1.12M 0.02% 339
2021
Q3
$4.57M Buy
95,712
+5,042
+6% +$253K 0.03% 302
2021
Q2
$4.51M Buy
+90,670
New +$4.36M 0.03% 351

Other funds holding GSK

Ray Dalio's GSK Position: Q1 2026 in Review

Ray Dalio reduced its GSK (GSK) stake by 51% in Q1 2026, selling an estimated $38.9M and leaving 698,666 shares worth $38.6M. The position accounts for 0.17% of the portfolio, ranked #89.

Ray Dalio first reported a position in GSK in Q2 2021 and has held it in 20 quarters since. The position peaked at $76M in Q4 2024. 1,034 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Ray Dalio held 698,666 shares of GSK worth $38.6M as of Q1 2026.
  • Ray Dalio sold 717,859 GSK shares in Q1 2026, an estimated $38.9M.
  • GSK made up 0.17% of Ray Dalio's portfolio in Q1 2026, its #89 holding.
  • Ray Dalio first reported a position in GSK in Q2 2021 and has held it in 20 quarters since.
  • Ray Dalio's GSK position peaked at $76M in Q4 2024.
  • 1,034 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.